← Leaderboards
John J Turchi
Wright State University
$8,990,550
Attributed
$10,881,075
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,881,075 · 9
By mechanism
R01$9,253,660 · 4
R41$660,202 · 2
R43$592,927 · 2
R21$374,286 · 1
Top collaborators
- Navnath S Gavande5 shared
- Katherine Pawelczak3 shared
- Robert Feltgen1 shared
Others in their field
Top investigators on “Dna Damage”
- Robert H Vonderheide · University Of Pennsylvania$45,163,553
- F Peter Guengerich · Vanderbilt University$33,973,148
- Aziz Sancar · University Of North Carolina Chapel Hill$31,216,731
- Robert O Wright · Brigham And Women'S Hospital$30,479,869
- John A Tainer · Scripps Research Institute$27,554,249
- Rosalind J Wright · Icahn School Of Medicine At Mount Sinai$27,391,656
Research focus
Dna DamageRepairedDna RepairMalignant NeoplasmsPathway InteractionsCellsResponseSmall MoleculeCisplatinMalignant Neoplasm Of LungBaseToxic EffectCancer CellMalignant Neoplasm Of OvaryInhibitor/AntagonistBiochemicalStructure-Activity RelationshipCombined Modality TherapyReplication Factor ARecombinational RepairMolecularNucleotide Excision RepairSignal TransductionHomologous Recombination
Grant awards (34)
Novel DNA damage response therapeutics targeting replication protein A$491,249
R01 · FY2025 · CA · contact PI
Discovery and development of Ku-targeted small molecule inhibitors: A novel mechanism of DNA-PK inhibition$555,248
R01 · FY2024 · CA · contact PI
Novel DNA damage response therapeutics targeting replication protein A$466,687
R01 · FY2024 · CA · contact PI
Discovery and development of Ku-targeted small molecule inhibitors: A novel mechanism of DNA-PK inhibition$572,781
R01 · FY2023 · CA · contact PI
Novel DNA damage response therapeutics targeting replication protein A$481,424
R01 · FY2023 · CA · contact PI
Discovery and development of Ku-targeted small molecule inhibitors: A novel mechanism of DNA-PK inhibition$572,781
R01 · FY2022 · CA · contact PI
Novel DNA damage response therapeutics targeting replication protein A$496,895
R01 · FY2022 · CA · contact PI
Discovery and development of Ku-targeted small molecule inhibitors: A novel mechanism of DNA-PK inhibition$584,470
R01 · FY2021 · CA · contact PI
Novel DNA damage response therapeutics targeting replication protein A$509,008
R01 · FY2021 · CA · contact PI
Discovery and development of Ku-targeted small molecule inhibitors: A novel mechanism of DNA-PK inhibition$603,569
R01 · FY2020 · CA · contact PI
Targeting nucleotide excision repair in combination cancer therapy$323,700
R01 · FY2017 · CA · contact PI
A new generation of targeted therapeutics for the treatment of cancer.$49,844
R41 · FY2017 · CA
Targeting nucleotide excision repair in combination cancer therapy$323,700
R01 · FY2016 · CA · contact PI
Chemical enhancement of CRISPR/Cas9 mediated site-specific genome engineering$293,005
R43 · FY2016 · GM
Targeting nucleotide excision repair in combination cancer therapy$323,700
R01 · FY2015 · CA · contact PI
Development of novel lung cancer therapeutics targeting the DNA damage response$249,431
R41 · FY2015 · CA
Targeting nucleotide excision repair in combination cancer therapy$313,989
R01 · FY2014 · CA · contact PI
Targeting nucleotide excision repair in combination cancer therapy$323,700
R01 · FY2013 · CA · contact PI
Development of Novel Agents Targeting Genome Stability and Maintenance for Treati$131,247
R41 · FY2013 · CA · contact PI
Targeting the ERCC1/XPF nuclease for cancer therapy$299,922
R43 · FY2012 · CA
Development of Novel Agents Targeting Genome Stability and Maintenance for Treati$229,680
R41 · FY2012 · CA · contact PI
Recognition and Repair of Cisplatin-DNA Damage$206,327
R01 · FY2011 · CA · contact PI
Recognition and Repair of Cisplatin-DNA Damage$212,708
R01 · FY2010 · CA · contact PI
Recognition and Repair of Cisplatin-DNA Damage$212,708
R01 · FY2009 · CA · contact PI
Development of methodologies for the analysis of DNA repair capacity to predict t$204,156
R21 · FY2009 · CA · contact PI
Recognition and Repair of Cisplatin-DNA Damage$212,708
R01 · FY2008 · CA · contact PI
Development of methodologies for the analysis of DNA repair capacity to predict t$170,130
R21 · FY2008 · CA · contact PI
Recognition and Repair of Cisplatin-DNA Damage$212,708
R01 · FY2007 · CA · contact PI
RECOGNITION AND REPAIR OF CISPLATIN DNA DAMAGE$193,050
R01 · FY2004 · CA
RECOGNITION AND REPAIR OF CISPLATIN DNA DAMAGE$193,050
R01 · FY2003 · CA
RECOGNITION AND REPAIR OF CISPLATIN DNA DAMAGE$264,550
R01 · FY2002 · CA
RECOGNITION AND REPAIR OF CISPLATIN DNA DAMAGE$264,550
R01 · FY2001 · CA
Validation of RPA as a Target for Cancer Chemotherapy$121,500
R01 · FY2001 · CA
RECOGNITION AND REPAIR OF CISPLATIN DNA DAMAGE$216,900
R01 · FY2000 · CA